Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
KalVista Pharma Analyst Ratings and Price Targets | NASDAQ:KALV | Benzinga
KalVista Pharmaceuticals Inc has a consensus price target of $24.44 based on the ratings of 11 analysts. The high is $32 issued by Stifel on June 8, 2022. The low is $19 issued by Citizens Capital Markets on March 26, 2025. The 3 most-recent analyst ratings were released by Needham, Needham, and Citizens Capital Markets on April 8, 2025, March 26, 2025, and March 26, 2025, respectively. With an average price target of $25 between Needham, Needham, and Citizens Capital Markets, there's an implied 113.86% upside for KalVista Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Citizens Capital Markets
Jones Trading
HC Wainwright & Co.
JMP Securities
1calculated from analyst ratings
Analyst Ratings for KalVista Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 139.52% | Needham | Serge Belanger66% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | 139.52% | Needham | Serge Belanger66% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | 62.53% | Citizens Capital Markets | Jonathan Wolleben68% | $19 → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2025 | Buy Now | 156.63% | Jones Trading | Debanjana Chatterjee23% | $30 → $30 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2025 | Buy Now | 139.52% | Needham | Serge Belanger66% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 62.53% | Citizens Capital Markets | Jonathan Wolleben68% | $19 → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/31/2025 | Buy Now | 62.53% | JMP Securities | Jonathan Wolleben68% | → $19 | Initiates | → Market Outperform | Get Alert |
| 01/07/2025 | Buy Now | 156.63% | TD Cowen | Stacy Ku3% | → $30 | Initiates | → Buy | Get Alert |
| 12/18/2024 | Buy Now | 88.2% | B of A Securities | Tazeen Ahmad54% | → $22 | Initiates | → Buy | Get Alert |
| 12/09/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos40% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/06/2024 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 139.52% | Needham | Serge Belanger66% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 199.4% | Jones Trading | Debanjana Chatterjee23% | → $35 | Initiates | → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan54% | — | Reiterates | → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2024 | Buy Now | 173.74% | Needham | Serge Belanger66% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 07/15/2024 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 173.74% | Needham | Serge Belanger66% | $35 → $32 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 199.4% | Needham | Serge Belanger66% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 71.09% | HC Wainwright & Co. | Andrew Fein63% | $24 → $20 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 199.4% | Needham | Serge Belanger66% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 199.4% | Needham | Serge Belanger66% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 105.3% | HC Wainwright & Co. | Andrew Fein63% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | 199.4% | Needham | Serge Belanger66% | $35 → $35 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | 105.3% | HC Wainwright & Co. | Andrew Fein63% | $16 → $24 | Maintains | Buy | Get Alert |
| 02/13/2024 | Buy Now | 199.4% | Needham | Serge Belanger66% | $22 → $35 | Maintains | Buy | Get Alert |
| 09/08/2023 | Buy Now | 36.87% | HC Wainwright & Co. | Andrew Fein63% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 71.09% | Cantor Fitzgerald | Charles Duncan54% | → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 07/10/2023 | Buy Now | 36.87% | HC Wainwright & Co. | Andrew Fein63% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2023 | Buy Now | 88.2% | Needham | Serge Belanger66% | → $22 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 182.29% | Cantor Fitzgerald | Charles Duncan54% | $49 → $33 | Maintains | Overweight | Get Alert |
| 03/10/2023 | Buy Now | 36.87% | HC Wainwright & Co. | Andrew Fein63% | → $16 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 88.2% | Needham | Serge Belanger66% | $24 → $22 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 71.09% | SVB Leerink | Joseph Schwartz64% | $30 → $20 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | 36.87% | HC Wainwright & Co. | Andrew Fein63% | $48 → $16 | Maintains | Buy | Get Alert |
| 10/05/2022 | Buy Now | 156.63% | SVB Leerink | Joseph Schwartz64% | $45 → $30 | Maintains | Outperform | Get Alert |
| 10/04/2022 | Buy Now | 105.3% | Needham | Serge Belanger66% | $38 → $24 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | 284.94% | SVB Leerink | Joseph Schwartz64% | $51 → $45 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | 225.06% | Needham | Serge Belanger66% | $42 → $38 | Maintains | Buy | Get Alert |
| 06/08/2022 | Buy Now | 173.74% | Stifel | Paul Matteis43% | $54 → $32 | Maintains | Buy | Get Alert |
FAQ
What is the target price for KalVista Pharma (KALV) stock?
The latest price target for KalVista Pharma (NASDAQ:KALV) was reported by Needham on April 8, 2025. The analyst firm set a price target for $28.00 expecting KALV to rise to within 12 months (a possible 139.52% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for KalVista Pharma (KALV)?
The latest analyst rating for KalVista Pharma (NASDAQ:KALV) was provided by Needham, and KalVista Pharma reiterated their buy rating.
When was the last upgrade for KalVista Pharma (KALV)?
There is no last upgrade for KalVista Pharma
When was the last downgrade for KalVista Pharma (KALV)?
There is no last downgrade for KalVista Pharma.
When is the next analyst rating going to be posted or updated for KalVista Pharma (KALV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating KalVista Pharma (KALV) correct?
While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a reiterated with a price target of $28.00 to $28.00. The current price KalVista Pharma (KALV) is trading at is $11.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
